Back to top
more

Twist Bioscience (TWST)

(Delayed Data from NSDQ)

$31.54 USD

31.54
644,436

+0.46 (1.48%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $31.53 -0.01 (-0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Twist Bioscience (TWST) Soars 12.5%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Twist Bioscience (TWST) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Sweta Killa headshot

5 Best Performing Stocks of the Top ETF of November

by Sweta Killa

ARK Innovation ETF (ARKK), which provides thematic multi-cap exposure to innovation across sectors, has gained 35.2%, becoming the best-performing ETF of November.

Twist Bioscience (TWST) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Twist Bioscience (TWST) delivered earnings and revenue surprises of 13.83% and 5.52%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Blueprint Medicines (BPMC) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Blueprint Medicines (BPMC) delivered earnings and revenue surprises of 7.95% and 14.09%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Bayer (BAYRY) Partners Twist Bioscience for Drug Discovery

by Zacks Equity Research

Bayer (BAYRY) collaborates with Twist Bioscience to advance breakthrough innovations based on new scientific approaches and platform technologies.

Twist Bioscience (TWST) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Twist Bioscience (TWST) delivered earnings and revenue surprises of 11.40% and 5%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Twist Bioscience (TWST) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Twist Bioscience (TWST) delivered earnings and revenue surprises of 2.75% and 6.31%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Horizon Therapeutics (HZNP) Q1 Earnings and Revenues Lag Estimates

by Zacks Equity Research

Horizon Therapeutics (HZNP) delivered earnings and revenue surprises of -29.06% and 7.16%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Twist Bioscience (TWST) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Twist Bioscience (TWST) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Twist Bioscience (TWST) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

by Zacks Equity Research

Twist Bioscience (TWST) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Twist Bioscience (TWST) Upgraded to Buy: Here's Why

by Zacks Equity Research

Twist Bioscience (TWST) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Wall Street Analysts Predict a 26.05% Upside in Twist Bioscience (TWST): Here's What You Should Know

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 26.1% in Twist Bioscience (TWST). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Twist Bioscience (TWST) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Twist Bioscience (TWST) delivered earnings and revenue surprises of 32.11% and 0.13%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Twist Bioscience (TWST) Upgraded to Buy: What Does It Mean for the Stock?

by Zacks Equity Research

Twist Bioscience (TWST) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Twist Bioscience (TWST) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Twist Bioscience (TWST) delivered earnings and revenue surprises of 28.91% and 0.56%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Palatin Technologies, Inc. (PTN) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Palatin Technologies, Inc. (PTN) delivered earnings and revenue surprises of 35.82% and 8.75%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Twist Bioscience (TWST) Surges 16.1%: Is This an Indication of Further Gains?

by Zacks Equity Research

Twist Bioscience (TWST) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Immuneering Corporation (IMRX) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Immuneering Corporation (IMRX) delivered earnings and revenue surprises of -2.08% and 92.17%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Aadi Bioscience, Inc. (AADI) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Aadi Bioscience, Inc. (AADI) delivered earnings and revenue surprises of 9.33% and 18.05%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Revance Therapeutics, Inc. (RVNC) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Revance Therapeutics, Inc. (RVNC) delivered earnings and revenue surprises of -37.65% and 0.90%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

NGM Biopharmaceuticals (NGM) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

NGM Biopharmaceuticals (NGM) delivered earnings and revenue surprises of 3.28% and 12.66%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Should You Invest in the SPDR S&P Biotech ETF (XBI)?

by Zacks Equity Research

Sector ETF report for XBI

Twist Bioscience (TWST) Upgraded to Buy: What Does It Mean for the Stock?

by Zacks Equity Research

Twist Bioscience (TWST) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Twist Bioscience (TWST) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Twist Bioscience (TWST) delivered earnings and revenue surprises of 16.92% and 9.35%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for XBI